Absolutely it could be done and is definitely relevant in identifying the true value of MSB's treatments. This is a bit above my pay grade but I'm sure there are many posters on here that could do this, I know that the CHF trial showed significant reductions in hospitalizations related to heart attacks and strokes. You could also argue that the higher survival benefit is more valuable/benefital to patients and so worth more $.
I just wanted to do some basic maths to show that Sorepocket's pricing argument is not valid. The current cost of msb products is one of the reasons MSB is targeting these indications... Large unmet needs.
Absolutely it could be done and is definitely relevant in...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.040(3.88%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $4.797M | 4.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 126568 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 9484 | 17 |
View Market Depth
| Last trade - 14.53pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |